Abstract. Alendronate (4-amino-1-hydroxybutylidene-1,1-bisphosphonate) is a potent inhibitor of bone resorption.
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fragility cause impairment of daily activities in this population.
The primary endpoint of treating osteoporosis is therefore the prevention of bone fracture, but demonstrating a prophylactic effect of treatment on fracture may require a long observation period and a large sample size [2] .
For this reason, the clinical efficacy of therapy for osteoporosis is usually assessed by measuring bone mineral density, which is directly related to the incidence of bone fracture [3] . Measurement of bone mineral density is especially useful during the early phase of drug development.
In Japan, several preparations such as active vitamin D3 analogues [4, 5] , calcitonin [6] , vitamin K2 [7] , ipriflavone [8] , etidronate [9] and estrogen derivative [10] have been approved for the treatment of osteoporosis because these drugs increase the bone mass of patients with osteoporosis. Of these preparations, etidronate, a derivative of bisphosphonate, has been reported to be a potent inhibitor of bone resorption [11] . This compound had been reported to increase in lumbar bone mineral density by 2.4% from baseline and to decrease in serum osteocalcin significantly [9] . Recently, alendronate, a more potent inhibitor of bone resorption than etidronate [12] , was shown to have a significant preventative effect on fracture in a large-scale study of Caucasian patients with osteoporosis [131. Furthermore, alendronate increased lumbar bone mineral density by about 4% from the baseline at a daily dose of 5 mg/day [13] .
The treatment of osteoporosis with alendronate has been known to induce marked decrease in bone turnover [141. Although alendronate is expected to be used for the treatment of osteoporosis, its clinical efficacy has not been studied yet in the Asian population.
In the present study, we determined the effects of alendronate on bone mineral density and bone metabolic markers and evaluated the safety of the drug in Japanese patients with osteoporosis.
Methods

Methods and Subjects
The dose-response effects of alendronate were determined with alendronate 2.5-mg tablets, alendronate 10-mg tablets and placebo tablets that were identical in appearance. Three groups of patients were given either a 2.5-mg, a 10-mg or a placebo tablet once daily in the early morning after overnight fasting; the duration of treatment was 36 weeks. In all of the groups, calcium lactate was administered concomitantly as a basic medication at a dose of 2.3 g (300 mg as elemental calcium) once daily after the evening meal. The patients were allocated to one of the three dose groups in the order of enrollment at each medical institution according to randomized drug numbers enclosed in envelopes, which were opened as the patients enrolled in the study. The investigational products were supplied by Banyu Pharmaceutical Co., Ltd. and Teijin Limited.
Patient selection criteria
The patients were selected from three populations of Japanese women. One of the populations was women with an osteoporosis score of 4 or higher according to the diagnostic criteria established by the Study Group of Osteoporosis authorized by the Ministry of Health and Welfare [15] . From this population, outpatients aged less than 75 years were enrolled in the study. To minimize error in bone density measurement, women whose bone density was less than 0.6 g/cm2 (QDR-1000 equivalent [16] ) were excluded from the study.
The second population was women diagnosed as having postmenopausal osteopenia. From this population, women were enrolled within five years after natural menopause if lumbar bone density was 0.6-0.88 g/cm2 [16] .
The third population was women who had undergone artificial menopause. From this population, women were enrolled within three years after artificial menopause if they had not been subjected to radiation therapy. Patients with the potential to develop secondary osteoporosis or undesirable complications such as liver and renal disorders were excluded from the study.
The study protocol was reviewed by the Institutional Review Board of each participating institution. Prior to enrollment, all of the patients gave their consent to participate in the study after being provided with sufficient information about the study and related matters.
Monitored items
At the start of observation, thoracic and lumbar vertebrae roentgenograms were obtained and lumbar bone density was measured by dual energy X-ray absorptiometry (DXA). Lumbar bone mineral density was converted to the QDR-1000 equivalent value by means of the cross-calibration equation previously reported [16] . Other monitored parameters were serum Al-p, calcium (Ca), phosphorus (Pi), N-osteocalcin (ELISA; Teijin, Japan [17] ) and intact PTH (Nicols, USA [18] ), and urinary calcium (Ca), phosphorus (Pi), creatinine and deoxypyridinoline [19] . The urinary concentrations of deoxypyridinoline were measured by HPLC [19] . Serum and urine samples were obtained 0, 4, 8, 12, 24 and 36 weeks after treatment and the levels of the above mentioned parameters were measured at Teijin Bio Laboratories.
To evaluate the safety of alendronate, urinalysis was conducted and peripheral blood cell counts, hepatic and renal parameters, creatinine phosphokinase (CPK), cholesterol, Na, K and Cl were monitored. Subjective symptoms such as low back pain and other symptoms related to drug administration (adverse effects) were also monitored.
Data analysis
In each of the dose groups, the significance of changes from the baseline in bone density and bone metabolic parameters was examined by the rate of change at each evaluation point by using the Student's t-test (two-tailed) or the signed rank sum test (multiplicity was adjusted by Bonferroni type). Differences between the groups were analyzed by Fisher's restricted LSD test.
Prior to data analysis, the bone density measurement data were examined for reliability by the Bone Mass Assessment Committee, generally according to the method reported previously [5] .
All of the data were expressed as the mean ± SEM, except for the case of adjusted means.
Data handling and study sites The three populations of patients were pooled to examine the dose-response effects of alendronate. Further, to examine the effects of alendronate on bone density, the osteoporotic patients and postmenopausal women were analyzed separately.
As shown in Fig. 1 , a total of 113 patients were enrolled in the study, of whom 12 were excluded from all of the analyses for the reasons listed in the figure legend. Of the 101 evaluated patients, eight were excluded from the efficacy analysis because of adverse reactions in six cases and protocol violations with respect to drug administration in two. Of the 93 patients included in the efficacy analysis, 13 were excluded from the bone density analysis. Therefore, the total sample size was 80 patients for the bone density analysis, 93 patients for the efficacy analysis and 101 patients for the safety analysis. The background data of the patients are shown in Table 1 . There were no significant differences between the three groups in any of the background factors except for bone density measured by dual X-ray absorptiometry (DXA), which was significantly higher (P=0.038) in the placebo group (P group) than in the 2.5 mg/ day group (L group) and the 10 mg/day group (H group). Therefore, the significance of the change in bone mineral density was analyzed by analysis of covariance and adjusted means.
Safety analysis
The safety of alendronate was evaluated based on the occurrence of clinical symptoms, the causal relationship of the symptoms with the drug, and abnormal laboratory data.
The incidence of adverse effects did not differ between the groups but tended to increase with the dose, being 6.1% (2/33),14.3% (5/35) and 18.2%
(6/33) in the P, L and H groups, respectively. The adverse effects occurred primarily during the first 4 weeks of treatment.
Two and three patients in the L and H groups, respectively, were withdrawn from the study because of adverse effects. The incidence of abnormal laboratory data was lower (though not significantly) in the P group than in the L group and the H group, being 0% (0/33), 14.3% (5/35) and 12.1% (4/33), respectively. No serious adverse events were observed in any of the 101 patients evaluated for safety, and tolerability was similar in all the groups ( Table 2 ). The most 
Changes in bone density
Changes in bone mineral density were examined by per-protocol analysis in all evaluable patients (n=80) and were further analyzed in the following subgroups: patients diagnosed as having osteoporosis (n=45) and postmenopausal women (n=35). In the entire evaluable population, bone density increased after 36 weeks of treatment in the L group and the H group, with the rate of increase being 5.21 % (n=19) and 5.64% (n=19) from baseline (adjusted mean), respectively. In contrast, bone density decreased by -0.90% (n=21) in the P group (adjusted mean) (Fig. 2) . Although the increases in the L group and the H group were greater than the change in the P group (P<0.0o1), there was no significant difference between the L group and the H group in the increase (Fig. 2) . Similarly, in the subpopulations of osteoporotic patients and postmenopausal women, bone density increased more in the L and H groups than in the P group, but the response observed in osteoporotic patients (+7.2%, n=10 for L and +7.7%, n=10 for H) was greater than that observed in postmenopausal women (+3.6%, n=9 for L and +3.5%, n=9 for H; P<0.05) (Fig. 3) .
Changes in biochemical parameters
Changes in serum levels of Ca, Pi and Caregulating hormones: The serum Ca level decreased significantly in the L and H groups, showing a maximum rate of change of -3.2 ± 5.5% (n=24) at week 36 in the L group (P=0.009) and -3.2 ± 6.2% (n=26) at week 12 in the H group (P=0.015). In contrast, the serum level of Ca in the P group decreased by -1.7 ± 5.1% (n=20) at week 36 (P=0.161). The serum Pi level decreased significantly in the L and H groups, with the maximum rate of change from the baseline value being -8.0 ± 15.7% (n=23) at week 36 in the L group (P=0.024) and -10.7 ± 13.9% (n=24) at week 4 in the H group (P=0.001).
Urinary Ca excretion decreased in the L and H groups, with a rate of change of about -20 ± 50% between week 4 and week 12. Similarly, serum intact PTH showed a marked transient increase in the L (44 ± 74%; n=23, P=0.010, at week 8) and H (59 ± 75%; n=25, P=0.001, at week 4) groups between week 4 and week 12 (Fig. 4) , then returned to the basal level at week 36.
Changes in bone turnover markers: Serum Al-P activity decreased dose-dependently by -9.2 ± 15.6% (n=18, P=0.022), -22.5 ± 18.0% (n=23, P<0.001) and -35.1 ± 14.8% (n=20, P<0.001) at week 36 in the P, L and H groups, respectively. Serum N-osteocalcin also decreased dose-dependently by 20.6 ± 62.0% (n=21, P=0.144), -29.7 ± 25.1% (n=21, P<0.001) and -53.1 ± 25.1% (n=25, P<0.001) at week 36 in the P, L and H groups, respectively (Fig. 5) , and urinary deoxypyridinoline decreased dosedependently by -13.8 ± 26.2% (n=21, P=0.026), -40 .2 ± 20.4% (n=21, P<0.001) and -52.4 ± 18.3% (n=23, P<0.001) (Fig. 6 ).
Discussion
In many European countries and in the United States, alendronate is being used clinically for the treatment of osteoporosis because of its potent antiresorbing activity [12] . The effects of alendronate on bone density and fracture prevention have been established in Caucasians [13] . [20] and a lower dietary intake of calcium [21] . Because of these racial differences, the recommended drug dose established for Caucasians may not be appropriate for Asians. The present small-scale, single-blind study was therefore conducted in postmenopausal Japanese women to determine the dose-response effects of alendronate and to estimate the clinical dose of the drug in the Japanese population.
The study yielded the following three major findings. First, alendronate 2.5 and 10 mg/day significantly increased bone density not only in postmenopausal women with osteopenia but also in patients diagnosed as having osteoporosis, with no significant difference between the two dosage groups, but the percentage changes in BMD in osteopenia (+3.6% for L and +3.5% for H) were less than those in osteoporosis (+7.2% for L and +7.7% for H). This may be because the baseline bone density was higher in osteopenia than in osteoporotic patients.
Second, alendronate decreased bone turnover markers such as Al-P, osteocalcin and urinary deoxypyridinoline excretion, with significant differences between the two dosage groups in the effect.
Third, serum Ca and urinary Ca excretion were decreased by alendronate, probably because of inhibition of bone resorption.
At the same time, a corresponding transient increase was noted in the serum intact PTH level.
What must be considered is that the doseresponse effect of alendronate on bone turnover markers was not consistent with the bone density results.
Alendronate had a significant doseresponse effect on bone remodeling markers at dosages of 2.5 and 10 mg/day. This indicates that bone metabolic markers are more sensitive indices than bone density.
The effect of alendronate on bone density has been reported to increase continuously without saturation during one to two years of administration in European and American populations [221.
A dose-response effect on bone density will therefore probably be observed in Japanese women in further investigations involving longer periods of administration.
The clinical dose of alendronate is 10 mg/day in Caucasians [13] . In the Japanese women who participated in the present study, the bone-densityincreasing effect of alendronate was not significantly different at daily doses of 2.5 and 10 mg.
This indicates that alendronate will be efficacious at a lower dose in Japanese than in Caucasian populations.
We administered a calcium preparation at a dosage of 300 mg/day of elemental calcium to all of the patients as a basic medication, based primarily on ethical consideration of the patients receiving a placebo and also to inhibit excessive secondary hyperparathyroidism that may occur because of excessive inhibition of bone resorption, but a transient increase in intact PTH was still observed with a significant decrease in serum Ca in patients receiving alendronate 2.5 and 10 mg/ day. This phenomenon has also been observed in Caucasian populations and suggests that, similarly to estrogen [23] , alendronate characteristically induces a transient secondary hyperparathyroidism independently of regular Ca intake [22] .
Secondary metabolic changes may explain the transient increase in intact PTH. For instance, increased PTH secretion promotes the production of 1,25(OH) 2-D [23] when the vitamin D activation mechanism is functionally normal.
Although the mechanism of the increase in intact PTH during the administration of alendronate has not been elucidated, it can be concluded that no excessive secondary hyperparathyroidism will be induced in Japanese patients if a calcium preparation is given concomitantly at a dosage of 300 mg/day.
Conclusions
Alendronate significantly increased bone density and noticeably reduced the level of bone turnover markers in postmenopausal Japanese women when administered at doses of 2.5 and 10 mg/day for 36 weeks. No particular safety concerns were noted during the 36-week treatment period.
Based on these results, the positive effect of alendronate on bone density can be hypothesized at a lower dose in Japanese than in Caucasian patients. 
